Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone

References

• UcokAIncesuCAkerTSexual dysfunction in patients with schizophrenia on antipsychotic medicationEur Psychiatry20072232833317344032
   PubMed Web of Science ®Google Scholar
• KnegteringHvan der MoolenAECasteleinSWhat are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?Psychoneuroendocrinology20032810912312650685
   PubMed Web of Science ®Google Scholar
• KnegteringHBoksMBlijdCA randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioningJ Sex Marital Ther20063231532616709552
   PubMed Web of Science ®Google Scholar
• KimKSPaeCUChaeJHEffects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidoneJ Clin Psychiatry20026340841312019665
   PubMed Web of Science ®Google Scholar
• DossenbachMHodgeAAndersMPrevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimationInt J Neuropsychopharmacol2005819520115631645
   PubMed Web of Science ®Google Scholar
• CostaAMLimaMSMari JdeJA systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophreniaSao Paulo Med J200612429129717262163
   PubMedGoogle Scholar
• OlfsonMUttaroTCarsonWHMale sexual dysfunction and quality of life in schizophreniaJ Clin Psychiatry20056633133815766299
   PubMed Web of Science ®Google Scholar
• CutlerAJSexual dysfunction and antipsychotic treatmentPsychoneuroendocrinology200328Suppl 1698212504073
   PubMed Web of Science ®Google Scholar
• RosenbergKPBleibergKLKoscisJA survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on complianceJ Sex Marital Ther20032928929614504017
   PubMed Web of Science ®Google Scholar
• HaddadPMWieckAAntipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and managementDrugs2004642291231415456328
   PubMed Web of Science ®Google Scholar
• GhadirianAMChouinardGAnnableLSexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatientsJ Nerv Ment Dis19821704634676124580
   PubMed Web of Science ®Google Scholar
• BreierAFMalhotraAKSuTPClozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine responseAm J Psychiatry19991562942989989566
   PubMed Web of Science ®Google Scholar
• CrawfordAMBeasleyCMJrTollefsonGDThe acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrationsSchizophr Res19972641549376336
   PubMed Web of Science ®Google Scholar
• RubinRTProlactin and schizophreniaMeltzerHYPsychopharmacology: The Third GenerationNew YorkRaven Press1987803808
   Google Scholar
• HalbreichUKinonBJGilmoreJAElevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effectsPsychoneuroendocrinology200328Suppl 1536712504072
   PubMed Web of Science ®Google Scholar
• KinonBJGilmoreJALiuHPrevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidonePsychoneuroendocrinology200328556812650681
   PubMed Web of Science ®Google Scholar
• SchwartzMFBaumanJEMastersWHHyperprolactinemia and sexual disorders in menBiol Psychiatry1982178618767115837
   PubMed Web of Science ®Google Scholar
• LundbergPOHulterBSexual dysfunction in patients with hypothalamopituitary disordersExp Clin Endocrinol19919881881778235
   PubMedGoogle Scholar
• BuvatJHyperprolactinemia and sexual function in men: a short reviewInt J Impot Res20031537337714562140
   PubMed Web of Science ®Google Scholar
• BuvatJLemaireABuvat-HerbautMHyperprolactinemia and sexual function in menHorm Res1985221962034054839
   PubMedGoogle Scholar
• KadiogluPYalinASTiryakiogluOSexual dysfunction in women with hyperprolactinemia: a pilot study reportJ Urol20051741921192516217346
   PubMed Web of Science ®Google Scholar
• TurnaBApaydinESemerciBWomen with low libido: correlation of decreased androgen levels with female sexual function indexInt J Impot Res20051714815315592425
   PubMed Web of Science ®Google Scholar
• CaseyDETardive dyskinesia and atypical antipsychotic drugsSchizophr Res199935SupplS61S6610190226
   PubMed Web of Science ®Google Scholar
• CaroffSNMannSCCampbellECMovement disorders associated with atypical antipsychotic drugsJ Clin Psychiatry200263Suppl 4121911913670
   PubMed Web of Science ®Google Scholar
• TenbackDEvan HartenPNSlooffCJEffects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) StudyJ Clin Psychiatry2005661130113316187770
   PubMed Web of Science ®Google Scholar
• WeidenPJEPS profiles: the atypical antipsychotics are not all the sameJ Psychiatr Pract200713132417242588
   PubMedGoogle Scholar
• Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychoticsJ Clin Psychiatry199859Suppl 121722
   Google Scholar
• AltamuraACMauriMCDe NovellisFResidual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrinePharmacopsychiatry1989222462492616635
   PubMed Web of Science ®Google Scholar
• GlazerWMMorgensternHDoucetteJTPredicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medicationsJ Clin Psychiatry1993541331398098030
   PubMed Web of Science ®Google Scholar
• MorgensternHGlazerWMIdentifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia StudyArch Gen Psychiatry1993507237338102845
   PubMed Web of Science ®Google Scholar
• KrebsMLeopoldKHinzpeterACurrent schizophrenia drugs: efficacy and side effectsExpert Opin Pharmacother200671005101616722811
   PubMed Web of Science ®Google Scholar
• StrassnigMBrarJSGanguliRIncreased caffeine and nicotine consumption in community-dwelling patients with schizophreniaSchizophr Res20068626927516859897
   PubMed Web of Science ®Google Scholar
• HendersonDCBorbaCPDaleyTBDietary intake profile of patients with schizophreniaAnn Clin Psychiatry2006189910516754415
   PubMedGoogle Scholar
• RegierDAFarmerMERaeDSComorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) StudyJAMA1990264251125182232018
   PubMed Web of Science ®Google Scholar
• KapurSZipurskyRJonesCRelationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophreniaAm J Psychiatry200015751452010739409
   PubMed Web of Science ®Google Scholar
• KapurSRemingtonGJonesCHigh levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET studyAm J Psychiatry19961539489508659621
   PubMed Web of Science ®Google Scholar
• NordströmALFardeLWieselFACentral D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patientsBiol Psychiatry1993332272358097114
   PubMed Web of Science ®Google Scholar
• KapurSZipurskyRBRemingtonGClinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophreniaAm J Psychiatry19991562862939989565
   PubMed Web of Science ®Google Scholar
• SchlegelSSchlösserRHiemkeCProlactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECTPsychopharmacology (Berl)19961242852878740053
   PubMed Web of Science ®Google Scholar
• FardeLNordströmALWieselFAPositron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effectsArch Gen Psychiatry1992495385441352677
   PubMed Web of Science ®Google Scholar
• MizrahiRRusjanPAgidOAdverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophreniaAm J Psychiatry200716463063717403977
   PubMed Web of Science ®Google Scholar
• SaeediHRemingtonGChristensenBKImpact of haloperidol, a dopamine D2 antagonist, on cognition and moodSchizophr Res20068522223116679001
   PubMed Web of Science ®Google Scholar
• de HaanLLavalayeJLinszenDSubjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidoneAm J Psychiatry20001571019102010831489
   PubMed Web of Science ®Google Scholar
• BressanRACostaDCJonesHMTypical antipsychotic drugs – D(2) receptor occupancy and depressive symptoms in schizophreniaSchizophr Res200256313612084417
   PubMed Web of Science ®Google Scholar
• ClaytonAHMcGarveyELClavetGJThe Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validityPsychopharmacol Bull1997337317459493486
   PubMed Web of Science ®Google Scholar
• SimpsonGMAngusJWA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
   PubMedGoogle Scholar
• BarnesTRA rating scale for drug-induced akathisiaBr J Psychiatry19891546726762574607
   PubMed Web of Science ®Google Scholar
• MunetzMRBenjaminSHow to examine patients using the Abnormal Involuntary Movement ScaleHosp Community Psychiatry198839117211772906320
   PubMedGoogle Scholar
• DoreyGIs smoking a cause of erectile dysfunction? A literature reviewBr J Nurs20011045546512070390
   PubMedGoogle Scholar
• GoffDCHendersonDCAmicoECigarette smoking in schizophrenia: relationship to psychopathology and medication side effectsAm J Psychiatry1992149118911941503131
   PubMed Web of Science ®Google Scholar
• van der WeideJSteijnsLSvan WeeldenMJThe effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirementPharmacogenetics20031316917212618594
   PubMedGoogle Scholar
• MontejoALRico-VillademorosFPsychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disordersJ Sex Marital Ther20083422723918398761
   PubMed Web of Science ®Google Scholar